Results 211 to 220 of about 106,775 (245)
Some of the next articles are maybe not open access.
Cardioprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Kardiologiia, 2014In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications ...
A S, Ametov +2 more
openaire +2 more sources
Inhibitory effects of glucagon-like peptide-1 receptor on epilepsy
Biochemical and Biophysical Research Communications, 2019Glucagon-like peptide-1 (GLP-1) and its receptor, GLP-1R, are valuable tools in the therapy of type 2 diabetes mellitus. Although GLP-1R stimulation is also potentially applicable to neurological disorders, few investigators have evaluated its beneficial effects in neurological disease models.
Yuetao Wen +5 more
openaire +2 more sources
[Glucagon-like peptide-1 receptor agonists].
Nihon rinsho. Japanese journal of clinical medicine, 2015Recently, the number of diabetic patients with obesity has increased by changes in life-style including food and physical exercise. Appearance of incretin-related drugs has given us more options for treating type 2 diabetes, and they are evaluated in regard to realizing appropriately controlled glycemic status.
Yamato, Mashimo, Kazuhiro, Eto
openaire +1 more source
The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists
Current Medicinal ChemistryAbstract: Diabetes mellitus has become a serious life-threatening disease. As one of the new drugs for the treatment of diabetes, GLP-1 receptor agonists have attracted a lot of attention. Compared with traditional hypoglycemic drugs, GLP-1 receptor agonists have good safety and tolerability. To a certain extent, they overcome the problem of the short
Haowen, Fang, Bing, Niu, Qin, Chen
openaire +2 more sources
Glucagon-like peptide 1 receptor
AfCS-Nature Molecule Pages, 2005Dieter Hoersch +2 more
openaire +1 more source
Glucagon-like peptide-1 receptor agonists
2016Native glucagon-like peptide-1 (GLP-1) is not practical for therapeutic use due to a short half-life caused by ubiquitous, fast, and effective in vivo degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
openaire +1 more source
Glucagon-Like Peptide-1 Receptor Agonists in Gynecologic Surgery
Obstetrics & GynecologyGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have rapidly expanded beyond their initial role in diabetes management to become prominent agents for weight loss and metabolic optimization. A growing number of patients receiving these therapies are presenting for gynecologic surgery. This narrative review summarizes current evidence on GLP-1 RAs,
Richard, Hsu +3 more
openaire +2 more sources
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease
International Journal of COPD, 2023Jun Chen
exaly